Altamira Therapeutics Ltd.
CYTOF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601936
No open-market purchases or sales by Altamira Therapeutics Ltd. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Altamira Therapeutics Ltd. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 7
- −8 vs. Q3 2022
- Shares held
- 7.14K
- −411.2K (−98.3%) vs. Q3 2022
- Total value
- $34.5K
- −$84.5K (−71.0%) vs. Q3 2022
- New holders
- 0
- 0 more added
- Sold out
- 8
- 7 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTOF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 1 | $0 |
| Q4 2024 | 2 | $1.21K |
| Q3 2024 | 5 | $71.3K |
| Q2 2024 | 4 | $2.95K |
| Q1 2024 | 3 | $3.47K |
| Q4 2023 | 4 | $26.7K |
| Q3 2023 | 9 | $217.2K |
| Q2 2023 | 6 | $47.3K |
| Q1 2023 | 7 | $7.26K |
| Q4 2022 | 7 | $34.5K |
| Q3 2022 | 15 | $119.0K |
| Q2 2022 | 14 | $142.0K |
| Q1 2022 | 18 | $607.0K |
| Q4 2021 | 19 | $1.03M |
| Q3 2021 | 17 | $1.34M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Altamira Therapeutics Ltd.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 3,847 | $18.7K | 0.00% | −4,286−52.7% | Reduced |
| Morgan Stanley | 2,495 | $12.1K | 0.00% | −56,236−95.8% | Reduced |
| Group One Trading, L.P. | 748 | $3.63K | 0.00% | −64,028−98.8% | Reduced |
| Wells Fargo & Company | 25 | $121 | 0.00% | −475−95.0% | Reduced |
| Stonebridge Capital Advisors LLC | 5 | $24 | 0.00% | −95−95.0% | Reduced |
| Cutler Group LP | 10 | $0 | 0.00% | −3,090−99.7% | Reduced |
| Advisor Group Holdings, Inc. | 15 | $0 | 0.00% | −295−95.2% | Reduced |
| Virtu Financial LLC | 0 | $0 | 0.00% | −124,787−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −64,820−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −23,303−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −19,946−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −23,415−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −18,871−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −7,552−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −5−100.0% | Sold out |